Sangamo Therapeutics Inc
(NAS:SGMO)
$
2.16
0.42 (24.14%)
Market Cap: 449.76 Mil
Enterprise Value: 363.62 Mil
PE Ratio: 0
PB Ratio: 19.64
GF Score: 42/100 Sangamo Therapeutics Inc at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019 / 12:10PM GMT
Release Date Price:
$10.39
(-2.17%)
Unidentified Analyst
(technical difficulty)
Therapeutics.
Before we get into the Q&A, I have to read a disclosure. So before we get started, I just need to let you know that for all important disclosures, please see the Morgan Stanley research disclosures website at www.morganstanley.com/researchdisclosures.
Okay. Sandy, thank you for being with us.
Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director
My pleasure.
Unidentified Analyst
So before we get into kind of program-specific Q&A, maybe it's good if you could just provide a couple of minutes of opening remarks about some of your key corporate highlights and then we can go from there.
Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director
Thank you. So Sangamo is a fascinating company. It's a genomic medicine company, and we can do gene therapy, cell
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot